Equities Analysts Offer Predictions for ANIP Q1 Earnings

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for ANI Pharmaceuticals in a research report issued on Monday, March 3rd. HC Wainwright analyst O. Livnat expects that the specialty pharmaceutical company will post earnings of $1.13 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $94.00 target price on the stock. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.86 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals’ Q2 2025 earnings at $1.31 EPS, Q3 2025 earnings at $1.13 EPS, Q4 2025 earnings at $1.53 EPS, FY2025 earnings at $5.10 EPS and FY2026 earnings at $5.81 EPS.

ANIP has been the topic of several other reports. Leerink Partners began coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective on the stock. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. StockNews.com downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday. Finally, Guggenheim boosted their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $79.00.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock opened at $59.68 on Thursday. The stock’s 50-day simple moving average is $57.42 and its 200-day simple moving average is $58.10. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -108.51 and a beta of 0.74. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. US Bancorp DE grew its stake in shares of ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after buying an additional 531 shares during the last quarter. KBC Group NV grew its stake in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at approximately $166,000. Finally, HighTower Advisors LLC bought a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $222,000. Institutional investors own 76.05% of the company’s stock.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,300 shares of company stock valued at $584,009 over the last ninety days. 12.70% of the stock is owned by insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.